Jeremy's friend's  Instablog

Jeremy's friend
Send Message
Looking for good articles.
  • Pfizer,Merck Interested In Amarin's VASCEPA 0 comments
    Sep 7, 2012 4:32 PM | about stocks: AMRN, PFE, MRK

    As VASCEPA is getting to be launched by Amarin Corp.,Pfizer and Merck are talking to Amarin's CEO Joe Zakrzewski.

    The talks in April,2011 broke down due to many uncertainties about Amarin's patent protection. Only Marine trial data for>500mg triglyceride was available.

    During last 15 months,Amarin put great effort in Intellectual property protection .Even "889" patent is now going to be issued.The examiner stated in approval:

    Lovaza and Triplix both raise LDL--which are known as causing cardiovascular problems.

    Now,FDA has asked Glaxo to change labeling for Lovaza to reflect Atrial Fibrillation risk.

    Amarin's patents protect VASCEPA to 2030,thus ensuring sales stability, 2 billion$/year and therefore higher Discounted Cash Flows.

    Also,Anchor trial 3 data reveals that 200mg-500mg population benefited significantly .So VASCEPA should get FDA approval by Aug.,2013. This adds 4-6 billion$ sales to 2 billion$ sales for > world wide.

    Reduce-It study should help FDA approval for stronger advertising message about the lowered risks from Vascepa for Cardio-problems. A similar study-JELIS was done in Japan from 1999-2005 and Epadel was shown to reduce Cardio events significantly.

    So we should be hearing soon--whether Pfizer will enter into marketing partnership like they did for Lipitor or MERCK will start a bidding war now.

    Disclosure: I am long AMRN.

    Stocks: AMRN, PFE, MRK
Back To Jeremy's friend's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers

Latest Comments

Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.